Could the Endocannabinoid System Offer a New Treatment Target for Obsessive Compulsive Disorder?
The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute to the pathogenesis of the disorder. This latest study, published in Cannabis and Cannabinoid Research, suggests that the endocannabinoid system (ECS) plays a role in OCD symptomsRead
